Skip to content
MarketScale
‹ Back to IndustriesHealthcare

HPS Helps Patients Understand their Healthcare Bills and Control Costs

After years of double-digit growth, healthcare costs are stabilizing. Unfortunately, they are still increasing by about 6.5% per year — much faster than the overall inflation rate—and this trend is expected to continue unabated. Employers, insurers, and patients are seeking ways to adjust health insurance plans to keep this rate of growth in check. Health Payment Systems…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

After years of double-digit growth, healthcare costs are stabilizing. Unfortunately, they are still increasing by about 6.5% per year — much faster than the overall inflation rate—and this trend is expected to continue unabated. Employers, insurers, and patients are seeking ways to adjust health insurance plans to keep this rate of growth in check. Health Payment Systems (HPS) can help.

A greater portion of rising health care costs is being shouldered by employees, adding additional pressure to their already stressful lives. A recent PwC report found that in order to keep their expenses in check, employers are increasingly turning to high deductible health plans (HDHPs). In fact, it was found that a quarter of those employers studied had high-deductible health plans already in place, while another 39% were considering moving to a HDHP-only strategy within the next three years. In addition, 36% of employers are considering a defined contribution strategy. In this approach, employers provide a set sum of money to each employee to pay for healthcare, and if the plan exceeds that sum, the employee is on the hook for the balance.

There are two major factors affecting healthcare costs – the prices of services and drugs, and the amount of healthcare being used by consumers. While its logical to assume drug and service costs would be the principal impetus behind these cost increases; it is, however, more people consuming more care that is the primary driver. Retail clinics and urgent care centers have expanded low-cost access to a greater audience of patients, encouraging greater utilization of their facilities. Another cost propelling factor, though, is the growing use of mental health care services.

Employers must take action to help ease the burden of higher healthcare costs on their employees. HPS tools can make a huge difference. Consolidated bills with Explanation of Benefits (EOBs) and payment plans help patients better understand and control the money their family spends on healthcare.

HPS offers employers:

  • A lower than market healthcare cost trend year over year for employers
  • Access to the largest independent network of healthcare providers across Wisconsin
  • A consolidated statement of bills and EOBs, as well as payment plans to support employees in understanding and controlling the money their family spends on healthcare

To learn more, visit us online today! .

Read more at https://www.hps.md/Healthcare-bills

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended AstraZeneca and Daiichi Sankyo’s Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly is investing $6.5 billion in a Houston manufacturing facility set to open around 2030, primarily to scale production of Foundayo, its oral GLP-1 treatment. The project signals a broader shift in U.S. pharmaceutical manufacturing reshoring and underscores the supply chain challenge of forecasting demand and building capacity years in advance for breakthrough therapeutics.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain: Lilly's CEO noted that one-third of new GLP-1 pill patients are now choosing Foundayo, illustrating fast-moving market share shifts that complicate production planning years in advance
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

Waiting for perfectly clean data is stalling healthcare AI, not protecting it

Healthcare organizations often delay AI initiatives waiting for perfectly clean data, but this assumption no longer holds: reliable subsets and synthetic data allow projects to start now while data work continues in parallel. Success requires starting with business outcomes rather than technology capabilities, and embedding governance in product strategy before implementation, not after.

  • 01Waiting for 100% clean data is effectively a decision never to start; hospital AI projects can begin on reliable data subsets while quality work continues in parallel.
  • 02Frame AI decisions around business outcomes (revenue growth, cost reduction, competitive advantage, new products, or ecosystem influence) rather than asking what AI can do.
  • 03Governance should be part of product strategy before design or purchase, especially as agentic AI takes actions—such as handling many revenue-cycle denials—while routing the rest to humans.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512